Kodiak Sciences logo

Kodiak SciencesNASDAQ: KOD

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

04 October 2018

Next earnings report:

28 March 2025

Last dividends:

N/A

Next dividends:

N/A
$309.69 M
-94%vs. 3y high
60%vs. sector
-vs. 3y high
-vs. sector
-76%vs. 3y high
51%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 8 min ago
$5.88+$0.13(+2.17%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

KOD Latest News

Kodiak Sciences to Participate in Upcoming Investor Conferences
prnewswire.com11 November 2024 Sentiment: POSITIVE

PALO ALTO, Calif. , Nov. 11, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences.

Kodiak Sciences to Present at Innovate Retina 2024
https://www.prnewswire.com/news-releases/kodiak-sciences-to-present-at-innovate-retina-2024-302275636.html14 October 2024 Sentiment: POSITIVE

PALO ALTO, Calif. , Oct. 14, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today its participation in a presentation and panel at Innovate Retina 2024 on October 17, 2024, in Chicago, Illinois.

Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
zacks.com10 October 2024 Sentiment: POSITIVE

KOD is evaluating tarcocimab in a phase III diabetic retinopathy study, which is set to form the basis for a regulatory filing across three eye disease indications.

Why Is Kodiak Sciences (KOD) Down 8.1% Since Last Earnings Report?
zacks.com13 September 2024 Sentiment: NEUTRAL

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

Kodiak (KOD) Q2 Loss Narrower Than Expected, Pipeline in Focus
zacks.com16 August 2024 Sentiment: POSITIVE

Kodiak (KOD) reports a narrower-than-expected loss for the second quarter of 2024. The company provides updates regarding its pipeline development plans.

Should You Hold Kodiak Sciences (KOD) Stock in Your Portfolio?
zacks.com20 June 2024 Sentiment: POSITIVE

Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for diabetic retinopathy, which is expected to support a regulatory filing for three eye disease indications.

Why Is Kodiak Sciences (KOD) Down 26.2% Since Last Earnings Report?
zacks.com14 June 2024 Sentiment: NEGATIVE

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?

Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
prnewswire.com29 May 2024 Sentiment: POSITIVE

PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that management will present at the following upcoming investor conferences: Jefferies Healthcare Conference, June 6, 2024, 8:00 AM ET (5:00 AM PT), New York, New York Goldman Sachs 45th Annual Global Healthcare Conference, June 13, 2024, 8:00 AM ET (5:00 AM PT), Miami Beach, Florida A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.

Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
zacks.com16 May 2024 Sentiment: POSITIVE

Kodiak (KOD) announces strong first-quarter 2024 results and shares progress on its pipeline development strategies.

Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Zacks Investment Research04 April 2024 Sentiment: POSITIVE

Kodiak (KOD) initiates a phase III study evaluating tarcocimab in diabetic retinopathy, which is expected to serve as the basis for a regulatory filing for three eye disease indications.

  • 1(current)

What type of business is Kodiak Sciences?

Kodiak Sciences Inc. is an independent biopharmaceutical company engaged in research, development, and commercialization of innovative biopharmaceutical drugs for the treatment of common eye diseases. Founded in June 2009, it is headquartered in Palo Alto, California. Kodiak Sciences Inc. does not have any developed drugs approved for commercial sale, and the company does not generate revenue from their sale. The company does not expect to generate revenue from sales until it completes development and clinical trials and receives regulatory approval for commercial sale of the developed drugs.

What sector is Kodiak Sciences in?

Kodiak Sciences is in the Healthcare sector

What industry is Kodiak Sciences in?

Kodiak Sciences is in the Biotechnology industry

What country is Kodiak Sciences from?

Kodiak Sciences is headquartered in United States

When did Kodiak Sciences go public?

Kodiak Sciences initial public offering (IPO) was on 04 October 2018

What is Kodiak Sciences website?

https://kodiak.com

Is Kodiak Sciences in the S&P 500?

No, Kodiak Sciences is not included in the S&P 500 index

Is Kodiak Sciences in the NASDAQ 100?

No, Kodiak Sciences is not included in the NASDAQ 100 index

Is Kodiak Sciences in the Dow Jones?

No, Kodiak Sciences is not included in the Dow Jones index

When was Kodiak Sciences the previous earnings report?

No data

When does Kodiak Sciences earnings report?

The next expected earnings date for Kodiak Sciences is 28 March 2025